(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
5 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally...
Stats | |
---|---|
本日の出来高 | 123 000 |
平均出来高 | 357 886 |
時価総額 | 121.62B |
EPS | ¥0 ( 2024-02-14 ) |
次の収益日 | ( ¥14.90 ) 2024-05-09 |
Last Dividend | ¥42.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 77.51 |
ATR14 | ¥0.594 (0.06%) |
ボリューム 相関
Takara Bio Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Takara Bio Inc. 相関 - 通貨/商品
Takara Bio Inc. 財務諸表
Annual | 2022 |
収益: | ¥78.14B |
総利益: | ¥44.77B (57.29 %) |
EPS: | ¥132.97 |
FY | 2022 |
収益: | ¥78.14B |
総利益: | ¥44.77B (57.29 %) |
EPS: | ¥132.97 |
FY | 2022 |
収益: | ¥67.70B |
総利益: | ¥49.21B (72.69 %) |
EPS: | ¥164.84 |
FY | 2021 |
収益: | ¥46.09B |
総利益: | ¥31.87B (69.16 %) |
EPS: | ¥79.29 |
Financial Reports:
No articles found.
Takara Bio Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥42.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥1.000 | 2012-03-28 |
Last Dividend | ¥42.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 13 | -- |
Total Paid Out | ¥114.10 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.77 | -- |
Div. Sustainability Score | 8.16 | |
Div.Growth Potential Score | 6.07 | |
Div. Directional Score | 7.12 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
7942.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7172.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
6413.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
5384.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4401.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3569.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2804.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
1414.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
9708.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
8725.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0330 | 1.500 | 9.34 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0128 | 1.200 | 9.57 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0141 | 1.500 | -0.954 | -1.431 | [0.1 - 1] |
payoutRatioTTM | 3.21 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 7.45 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.46 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.25 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 61.42 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 200.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 81.73 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.553 | 1.000 | 4.11 | 4.11 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0309 | 1.000 | -1.382 | -1.382 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.387 | 0.800 | -0.751 | -0.601 | [0.5 - 2] |
Total Score | 8.16 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 77.42 | 1.000 | 2.28 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0141 | 2.50 | -0.613 | -1.431 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 81.73 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.683 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 200.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 3.21 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.717 | 1.500 | 8.55 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.506 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 6.07 |
Takara Bio Inc.
Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。